• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在加拿大两个城市中心实施结合疫苗接种后,儿童肺炎球菌的基因组格局变化

Evolving genomic landscape of pediatric pneumococcus in two Canadian urban centers following conjugate vaccination.

作者信息

Teatero Sarah, McGeer Allison, Plevneshi Agron, Ricketson Leah J, Kellner James D, Fittipaldi Nahuel

机构信息

Public Health Ontario, Toronto, ON, Canada.

Department of Microbiology, Sinai Health System, Toronto, ON, Canada.

出版信息

Front Microbiol. 2025 Aug 18;16:1642658. doi: 10.3389/fmicb.2025.1642658. eCollection 2025.

DOI:10.3389/fmicb.2025.1642658
PMID:40901074
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12400966/
Abstract

BACKGROUND AND AIM

Pneumococcal conjugate vaccines (PCVs) have significantly reduced pediatric invasive pneumococcal disease (IPD). However, vaccine escape variants, the emergence of non-vaccine serotypes (NVTs), and antimicrobial resistance (AMR) remain ongoing concerns. We aimed to characterize long-term trends in serotype distribution, lineage composition, and AMR patterns among pediatric IPD cases following PCV introduction in two major Canadian urban centers: Calgary, Alberta, and Toronto, Ontario.

METHODS

We combined whole-genome sequencing with epidemiologic data from 818 pediatric IPD isolates collected through population-based, active surveillance in Calgary (1998-2016) and Toronto (2009-2016). Phylogenetic analyses, serotype characterization, and AMR profiling were performed to assess temporal trends across three vaccine eras.

RESULTS

PCV implementation reduced vaccine type serotypes but was followed by expansion of NVTs, including serotypes 22F, 33F, and 15B, with regional differences in prevalence. Serotypes 19A and 3 persisted despite PCV13 inclusion. Several pre-vaccine-associated lineages re-emerged under NVT capsules, indicating capsular switching. Macrolide resistance increased in Calgary (7.4-29.3%), distributed across multiple lineages; penicillin resistance remained infrequent.

CONCLUSION

Our findings highlight sustained pneumococcal adaptation through serotype replacement, vaccine escape, and AMR dissemination. Ongoing genomic surveillance is essential to monitor these trends and inform vaccination policies.

摘要

背景与目的

肺炎球菌结合疫苗(PCV)已显著降低儿童侵袭性肺炎球菌疾病(IPD)的发病率。然而,疫苗逃逸变异株、非疫苗血清型(NVT)的出现以及抗菌药物耐药性(AMR)仍是持续存在的问题。我们旨在描述加拿大两个主要城市中心(艾伯塔省卡尔加里市和安大略省多伦多市)引入PCV后儿童IPD病例血清型分布、谱系组成和AMR模式的长期趋势。

方法

我们将全基因组测序与来自卡尔加里市(1998 - 2016年)和多伦多市(2009 - 2016年)通过基于人群的主动监测收集的818株儿童IPD分离株的流行病学数据相结合。进行系统发育分析、血清型鉴定和AMR分析,以评估三个疫苗时代的时间趋势。

结果

PCV的实施降低了疫苗型血清型,但随后NVT出现扩张,包括22F、33F和15B血清型,患病率存在地区差异。尽管PCV13中包含了19A和3血清型,但它们仍然存在。在NVT荚膜下,几种疫苗接种前相关谱系重新出现,表明发生了荚膜转换。卡尔加里市的大环内酯类耐药性增加(从7.4%增至29.3%),分布于多个谱系;青霉素耐药性仍然少见。

结论

我们的研究结果突出了肺炎球菌通过血清型替代、疫苗逃逸和AMR传播持续发生适应性变化。持续的基因组监测对于监测这些趋势并为疫苗接种政策提供信息至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b394/12400966/8eb1b3a72c19/fmicb-16-1642658-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b394/12400966/95e89aec3516/fmicb-16-1642658-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b394/12400966/5383ac2f183b/fmicb-16-1642658-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b394/12400966/d2ed677f3893/fmicb-16-1642658-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b394/12400966/87473fea0ffe/fmicb-16-1642658-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b394/12400966/5d159cc23bf3/fmicb-16-1642658-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b394/12400966/8eb1b3a72c19/fmicb-16-1642658-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b394/12400966/95e89aec3516/fmicb-16-1642658-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b394/12400966/5383ac2f183b/fmicb-16-1642658-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b394/12400966/d2ed677f3893/fmicb-16-1642658-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b394/12400966/87473fea0ffe/fmicb-16-1642658-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b394/12400966/5d159cc23bf3/fmicb-16-1642658-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b394/12400966/8eb1b3a72c19/fmicb-16-1642658-g006.jpg

相似文献

1
Evolving genomic landscape of pediatric pneumococcus in two Canadian urban centers following conjugate vaccination.在加拿大两个城市中心实施结合疫苗接种后,儿童肺炎球菌的基因组格局变化
Front Microbiol. 2025 Aug 18;16:1642658. doi: 10.3389/fmicb.2025.1642658. eCollection 2025.
2
A decade of 10-valent pneumococcal conjugate vaccine use in Lithuania: trends in invasive pneumococcal serotype dynamics.立陶宛使用10价肺炎球菌结合疫苗的十年:侵袭性肺炎球菌血清型动态变化趋势
Front Public Health. 2025 Aug 1;13:1633396. doi: 10.3389/fpubh.2025.1633396. eCollection 2025.
3
Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis.肺炎球菌结合疫苗时代后引起儿童侵袭性疾病的肺炎链球菌血清型分布:一项系统评价和荟萃分析。
PLoS One. 2017 May 9;12(5):e0177113. doi: 10.1371/journal.pone.0177113. eCollection 2017.
4
Genomic analysis and pneumococcal population dynamics across PCV implementation in South Korea, 1997-2023.1997 - 2023年韩国肺炎球菌结合疫苗实施期间的基因组分析与肺炎球菌种群动态
Microb Genom. 2025 Jul;11(7). doi: 10.1099/mgen.0.001433.
5
Serotype distribution of invasive and non-invasive pneumococcal disease in children ≤5 years of age following the introduction of 10- and 13-valent pneumococcal conjugate vaccines in infant national immunization programs: a systematic literature review.在国家婴幼儿免疫规划中引入10价和13价肺炎球菌结合疫苗后,5岁及以下儿童侵袭性和非侵袭性肺炎球菌疾病的血清型分布:一项系统文献综述
Front Public Health. 2025 May 30;13:1544359. doi: 10.3389/fpubh.2025.1544359. eCollection 2025.
6
Streptococcus pneumoniae carriage, serotypes, genotypes, and antimicrobial resistance trends among children in Portugal, after introduction of PCV13 in National Immunization Program: A cross-sectional study.葡萄牙全国免疫计划引入 PCV13 后儿童肺炎链球菌携带、血清型、基因型和抗生素耐药趋势的横断面研究。
Vaccine. 2024 Sep 17;42(22):126219. doi: 10.1016/j.vaccine.2024.126219. Epub 2024 Aug 14.
7
Serotype distribution of invasive and non-invasive pneumococcal disease in adults ≥65 years of age following the introduction of 10- and 13-valent pneumococcal conjugate vaccines in infant national immunization programs: a systematic literature review.在婴儿国家免疫规划中引入10价和13价肺炎球菌结合疫苗后≥65岁成年人侵袭性和非侵袭性肺炎球菌疾病的血清型分布:一项系统文献综述
Front Public Health. 2025 May 30;13:1544331. doi: 10.3389/fpubh.2025.1544331. eCollection 2025.
8
Whole-genome sequencing, strain composition, and predicted antimicrobial resistance of Streptococcus pneumoniae causing invasive disease in England in 2017-20: a prospective national surveillance study.2017 - 2020年在英格兰引起侵袭性疾病的肺炎链球菌的全基因组测序、菌株组成及预测的抗菌药物耐药性:一项前瞻性全国监测研究
Lancet Microbe. 2025 Jul;6(7):101102. doi: 10.1016/j.lanmic.2025.101102. Epub 2025 May 24.
9
Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.14 价肺炎球菌多糖结合疫苗(PNEUBEVAX 14™)在 6-8 周龄健康印度婴儿中的免疫原性和安全性:一项单盲、随机、阳性对照、III 期研究。
Vaccine. 2024 May 10;42(13):3157-3165. doi: 10.1016/j.vaccine.2024.03.056. Epub 2024 Apr 17.
10
A comprehensive analysis of serotype-specific invasive capacity, clinical presentations, and mortality trends of invasive pneumococcal disease.对侵袭性肺炎球菌疾病的血清型特异性侵袭能力、临床表现及死亡率趋势的综合分析。
Vaccine. 2025 Feb 15;47:126692. doi: 10.1016/j.vaccine.2024.126692. Epub 2025 Jan 7.

本文引用的文献

1
Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a review.成年人(≥18 岁)从儿童肺炎球菌疫苗接种中获得的间接保护:综述。
Expert Rev Vaccines. 2024 Jan-Dec;23(1):997-1010. doi: 10.1080/14760584.2024.2416229. Epub 2024 Oct 28.
2
Cost-Effectiveness Analysis of Routine Childhood Immunization with 20-Valent versus 15-Valent Pneumococcal Conjugate Vaccines in Germany.德国20价与15价肺炎球菌结合疫苗用于儿童常规免疫的成本效益分析
Vaccines (Basel). 2024 Sep 12;12(9):1045. doi: 10.3390/vaccines12091045.
3
Effectiveness of the ten- and thirteen-valent pneumococcal conjugate vaccines to prevent serotype 19A invasive pneumococcal disease in Quebec, Canada. A Canadian immunization research network (CIRN) study.
十价和十三价肺炎球菌结合疫苗预防加拿大魁北克19A血清型侵袭性肺炎球菌疾病的有效性。一项加拿大免疫研究网络(CIRN)研究。
Vaccine. 2024 Dec 2;42(26):126379. doi: 10.1016/j.vaccine.2024.126379. Epub 2024 Sep 26.
4
Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1 + 1 infant schedule in England: a modelling study.在英格兰,1 + 1 婴儿免疫计划中用 15 价或 20 价肺炎球菌结合疫苗替代 13 价肺炎球菌结合疫苗的潜在影响:一项建模研究。
Lancet Public Health. 2024 Sep;9(9):e654-e663. doi: 10.1016/S2468-2667(24)00161-0. Epub 2024 Aug 14.
5
Invasive pneumococcal disease surveillance in Canada, 2021-2022.2021 - 2022年加拿大侵袭性肺炎球菌疾病监测
Can Commun Dis Rep. 2024 May 24;50(5):121-134. doi: 10.14745/ccdr.v50i05a02.
6
A narrative review of genomic characteristics, serotype, immunogenicity, and vaccine development of capsular polysaccharide.关于荚膜多糖的基因组特征、血清型、免疫原性及疫苗开发的叙述性综述
Clin Exp Vaccine Res. 2024 Apr;13(2):91-104. doi: 10.7774/cevr.2024.13.2.91. Epub 2024 Apr 30.
7
High-resolution genomics identifies pneumococcal diversity and persistence of vaccine types in children with community-acquired pneumonia in the UK and Ireland.高分辨率基因组学鉴定出英国和爱尔兰社区获得性肺炎儿童中肺炎球菌的多样性和疫苗类型的持续性。
BMC Microbiol. 2024 Apr 27;24(1):146. doi: 10.1186/s12866-024-03300-w.
8
Indirect impact of childhood 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian older adults: a Canadian Immunization Research Network (CIRN) retrospective observational study.加拿大老年人中儿童 13 价肺炎球菌结合疫苗(PCV13)的间接影响:加拿大免疫研究网络(CIRN)回顾性观察研究。
Thorax. 2024 Aug 19;79(9):861-869. doi: 10.1136/thorax-2023-220377.
9
Antimicrobial resistance of from invasive pneumococcal diseases in Latin American countries: a systematic review and meta-analysis.拉丁美洲国家侵袭性肺炎球菌疾病中 的抗菌药物耐药性:系统评价和荟萃分析。
Front Public Health. 2024 Jan 22;12:1337276. doi: 10.3389/fpubh.2024.1337276. eCollection 2024.
10
Pneumococcal Vaccine Breakthrough and Failure in Infants and Children: A Narrative Review.婴幼儿肺炎球菌疫苗的突破与失效:一项叙述性综述
Vaccines (Basel). 2023 Nov 24;11(12):1750. doi: 10.3390/vaccines11121750.